Synthesis of Amino-ADT Provides Access to Hydrolytically Stable Amide-Coupled Hydrogen Sulfide Releasing Drug Targets

Abstract

As additional physiological functions of hydrogen sulfide (H₂S) are discovered, developing practical methods for exogenous H₂S delivery is important. In particular, nonsteroidal anti-inflammatory drugs (NSAIDs) functionalized with H₂S-releasing anethole dithiolethione (ADT-OH) through ester bonds are being investigated for their combined anti-inflammatory and antioxidant potential. The chemical robustness of the connection between drug and H₂S-delivery components, however, is a key and controllable linkage in these compounds. Because esters are susceptible to hydrolysis, particularly under acidic conditions such as stomach acid in oral drug delivery applications, we report here a simple synthesis of amino-ADT (ADT-NH₂ ) and provide conditions for successful ADT-NH₂ derivatization with the drugs naproxen and valproic acid. Using UV-vis spectroscopy and HPLC analysis, we demonstrate that amide-functionalized ADT derivatives are significantly more resistant to hydrolysis than ester-functionalized ADT derivatives.

Key words

sulfur - dithiolethione - ADT-OH - hydrogen sulfide - H₂S donors

• References and Notes

• 1 Gadalla MM, Snyder SH. J. Neurochem. 2010; 113: 14
• 2 Wang R. Physiol. Rev. 2012; 92: 791
• 3 Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. Biochem. Biophys. Res. Commun. 2005; 338: 1547
• 4 Giuliani D, Ottani A, Zaffe D, Galantucci M, Strinati F, Lodi R, Guarini S. Neurobiol. Learn. Mem. 2013; 104: 82
• 5 Hu L.-F, Lu M, Tiong CX, Dawe GS, Hu G, Bian J.-S. Aging Cell 2010; 9: 135
• 6 Whiteman M, Winyard PG. Expert. Rev. Clin. Pharmacol. 2011; 4: 13
• 7 Szabo C, Papapetropoulos A. Br. J. Pharmacol. 2011; 164: 853
• 8 Zanardo RC. O, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. FASEB J. 2006; 20: 2118
• 9a Hui Y, Du J, Tang C, Bin G, Jiang H. J. Infect. 2003; 47: 155
• 9b Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FB. M, Whiteman M, Salto-Tellez M, Moore PK. FASEB J. 2005; 19: 1196
• 10 Collin M, Anuar FB. M, Murch O, Bhatia M, Moore PK, Thiemermann C. Br. J. Pharmacol. 2005; 146: 498
• 11 Gardiner SM, Kemp PA, March JE, Bennett T. Br. J. Pharmacol. 1999; 128: 1772
• 12 Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC. Cardiovasc. Res. 2007; 76: 29
• 13 Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski LK, Herndon DN, Wang R, Szabó C. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 21972
• 14 Jang H, Oh M.-Y, Kim Y.-J, Choi I.-Y, Yang HS, Ryu W.-S, Lee S.-H, Yoon B.-W. J. Neurosci. Res. 2014; 92: 1520
• 15a Song ZJ, Ng MY, Lee Z.-W, Dai W, Hagen T, Moore PK, Huang D, Deng L.-W, Tan C.-H. Med. Chem. Commun. 2014; 5: 557
• 15b Pluth MD, Bailey TS, Hammers MD, Hartle MD, Henthorn HA, Steiger AK. Synlett 2015; 26: 2633
• 16 Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Free Radical Biol. Med. 2007; 42: 706
• 17 Wallace JL, Caliendo G, Santagada V, Cirino G. Br. J. Pharmacol. 2010; 159: 1236
• 18 Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, Ramchandran R, Roberts DD. Br. J. Pharmacol. 2007; 151: 142
• 19 Giustarini D, Del Soldato P, Sparatore A, Rossi R. Free Radical Biol. Med. 2010; 48: 1263
• 20 Muzaffar S, Jeremy JY, Sparatore A, Del Soldato P, Angelini GD, Shukla N. Br. J. Pharmacol. 2008; 155: 984
• 21 Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E, Santucci L, Cirino G, Wallace JL. Br. J. Pharmacol. 2007; 150: 996
• 22 Hasegawa U, van der Vlies AJ. Bioconjugate Chem. 2014; 25: 1290
• 23 Xie G, Cheng K.-W, Huang L, Rigas B. Biochem. Pharmacol. 2014; 91: 249
• 24 Mizuno M, Yamano M. Org. Lett. 2005; 7: 3629
• 25a Molander GA, Ellis N. Acc. Chem. Res. 2007; 40: 275
• 25b Doucet H. Eur. J. Org. Chem. 2008; 2013
• 26a Alacid E, Nájera C. J. Org. Chem. 2009; 74: 8191
• 26b Molander GA, Barcellos T, Traister KM. Org. Lett. 2013; 15: 3342
• 27 Synthesis of 1 In a glovebox, 4-chloro(N-Boc)aniline (350 mg, 1.54 mmol), potassium trans-1-propenyltrifluoroborate (273 mg, 1.85 mmol), Pd(OAc)₂ (35 mg, 0.16 mmol), RuPhos (144 mg, 0.308 mmol), and Cs₂CO₃ (1.5 g, 4.6 mmol) were added to an oven-dried three-neck round-bottom flask fitted with a reflux condenser. The sealed apparatus was removed from the glovebox, and a degassed solvent mixture of 4:1 THF–water (10 mL) was added via syringe; minimal solvent aids with full conversion and overall yield. The reaction mixture was stirred at 80 °C under N₂ for 14 h, after which the solvent was removed by rotary evaporation. The residue was dissolved in EtOAc and filtered through Celite. The filtrate was washed with H₂O, brine, and dried with Na₂SO₄. The crude product was purified using column chromatography (20–50% hexane–EtOAc gradient) and further purified by recrystallization from hexanes to afford the pure product as a light brown solid (318 mg, 88% yield). ¹H NMR (500 MHz, DMSO): δ = 9.31 (s, 1 H), 7.38 (d, J = 8.5 Hz, 2 H), 7.24 (d, J = 8.6 Hz, 2 H), 6.31 (dd, J = 15.8, 1.43 Hz, 1 H), 6.11–6.18 (m, 1 H), 1.81 (dd, J = 6.56, 1.5 Hz, 3 H), 1.47 (s, 9 H) ppm. ¹³C{¹H} NMR (125 MHz, DMSO): δ = 152.67, 138.26, 131.34, 130.41, 125.94, 123.34, 118.08, 78.95, 28.11, 18.19 ppm. HRMS: m/z [M + Na]⁺ calcd for [NaC₁₄H₁₉NO₂]⁺: 256.1313; found: 256.1309.
• 28 Synthesis of ADT-NH₂ Compound 1 (100 mg, 0.429 mmol) and sulfur (96 mg, 3.0 mmol) were added to an oven-dried pressure vessel and dissolved in DMA (6 mL) under N₂, and the reaction was stirred at 180 °C for 18 h. After stirring, the solvent was removed under vacuum while heated at 40 °C. The crude residue was diluted with H₂O, extracted into EtOAc. The combined organic fractions were washed with brine and dried with Na₂SO₄. The compound was purified using column chromatography (3% MeOH–CH₂Cl₂) to afford the pure product as a dark brown solid (66 mg, 68% yield). ¹H NMR (500 MHz, CD₂Cl₂): δ = 7.51 (d, J = 8.7 Hz, 2 H), 7.36 (s, 1 H), 6.71 (d, J = 8.7 Hz, 2 H), 4.27 (br, 2 H) ppm. ¹³C{¹H} NMR (125 MHz, CD₂Cl₂): δ = 215.05, 174.86, 151.60, 133.66, 129.25, 121.63, 115.29 ppm. HRMS: m/z [M + H]⁺ calcd for [C₉H₈NS₃]⁺: 225.9819; found: 225.9823.
• 29a We note that although the synthesis of ADT-NH₂ is suggested in a patent,^29b the precursor to compound 1 in the patent application is not a known compound, and no preparation is presented.
• 29b Wallace J, Cirino G, Caliendo G, Sparatore A, Santagada V, Fiorucci S. US Patent 2007/0197479 A1, 2007
• 30 Chollet M, Legouin B, Burgot J.-L. J. Chem. Soc., Perkin Trans. 2 1998; 2227
• 31 Mosmann T. J. Immunol. Methods 1983; 65: 55